Tags : Drug-Resistant Infections

Brii Biosciences Collaborates with Qpex to Develop and Commercialize Antibiotics

Shots: Qpex Biopharm to receive up front, development, regulatory and commercial milestones with royalties on sales in the licensed territories. Brii Biosciences to get the license to develop, manufacture, and commercialize Qpex’s antibiotic portfolio in China including Taiwan, Hong Kong, Macau and the People’s Republic of China The Qpex’s portfolio includes OMNIvance, ORAvance and a […]Read More